Phase 1 High-Risk Clinical Trials
11 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma
High-Risk Localized Soft Tissue Sarcoma
Fudan University52 enrolled1 locationNCT05774275
Recruiting
Phase 1Phase 2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Peripheral T Cell LymphomaT-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic Leukemia+4 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 1
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
Prostate CancerLocalized Prostate CarcinomaHigh-risk Prostate Cancer+2 more
Thomas Hope45 enrolled1 locationNCT07054346
Recruiting
Phase 1
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Pancreatic CancerHigh-Risk Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins37 enrolled1 locationNCT05013216
Recruiting
Phase 1Phase 2
Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.
High-risk Prostate Cancer
Rabin Medical Center20 enrolled1 locationNCT07208240
Recruiting
Phase 1Phase 2
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
High-risk NMIBC
Shanghai Hengrui Pharmaceutical Co., Ltd.150 enrolled1 locationNCT05410730
Recruiting
Phase 1
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.170 enrolled1 locationNCT06108492
Recruiting
Phase 1Phase 2
To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd.24 enrolled6 locationsNCT06378242
Recruiting
Phase 1Phase 2
DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With AML
High-risk Soft Tissue Sarcoma
Affiliated Hospital to Academy of Military Medical Sciences30 enrolled1 locationNCT01898663
Recruiting
Phase 1Phase 2
The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma
High-Risk Localized Soft Tissue Sarcoma
Fudan University52 enrolled1 locationNCT05839275